Cargando…

Retraction of “Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial”

Detalles Bibliográficos
Autores principales:	Wang, Hai, Agarwal, Pranay, Zhao, Gang, Ji, Guang, Jewell, Christopher M., Fisher, John P., Lu, Xiongbin, He, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141583/ https://www.ncbi.nlm.nih.gov/pubmed/37122466 http://dx.doi.org/10.1021/acscentsci.3c00335

Ejemplares similares

Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial
por: Wang, Hai, et al.
Publicado: (2018)

Correction to Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial
por: Wang, Hai, et al.
Publicado: (2021)

Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance
por: Wang, Hai, et al.
Publicado: (2018)

Erratum: A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents
por: Wang, Hai, et al.
Publicado: (2016)

A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of therasnostic agents
por: Wang, Hai, et al.
Publicado: (2015)

Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance
por: Wang, Hai, et al.
Publicado: (2021)

Retraction Note: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
por: Janzen, D. M., et al.
Publicado: (2020)

Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer
por: Murillo, Dzohara, et al.
Publicado: (2023)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
por: McFadden, Melayshia, et al.
Publicado: (2021)

Nanoparticles of Metal-Organic Cages Overcoming Drug Resistance in Ovarian Cancer
por: Wang, Han, et al.
Publicado: (2019)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
por: Liu, Yunhua, et al.
Publicado: (2018)

Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment
por: Acter, Shahinur, et al.
Publicado: (2023)

Bioinspired One Cell Culture Isolates Highly Tumorigenic and Metastatic Cancer Stem Cells Capable of Multilineage Differentiation
por: Wang, Hai, et al.
Publicado: (2020)

Bioinspired One Cell Culture Isolates Highly Tumorigenic and Metastatic Cancer Stem Cells Capable of Multilineage Differentiation
por: Wang, Hai, et al.
Publicado: (2023)

Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
por: Xu, Jiangsheng, et al.
Publicado: (2019)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021)

Overcome cancer drug resistance by targeting epigenetic modifications of centrosome
por: Jia, Zan-Hui, et al.
Publicado: (2019)

An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
por: Janzen, D. M., et al.
Publicado: (2015)

Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells
por: Catanzaro, Daniela, et al.
Publicado: (2018)

Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models
por: Althurwi, Safiah Ibrahim, et al.
Publicado: (2020)

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study
por: Michalak, Marcin, et al.
Publicado: (2020)

Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration
por: Martano, Simona, et al.
Publicado: (2022)

Combating and overcoming drug resistance in cancer
por: Price, Douglas K.
Publicado: (2014)

Nanomedicines for Overcoming Cancer Drug Resistance
por: Hu, Tingting, et al.
Publicado: (2022)

Corrigendum: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
por: Janzen, D. M., et al.
Publicado: (2016)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
por: Huang, Linjuan, et al.
Publicado: (2023)

Design and Development of Nanomaterial-Based Drug Carriers to Overcome the Blood–Brain Barrier by Using Different Transport Mechanisms
por: Song, Jisu, et al.
Publicado: (2021)

Recent Application of Nanomaterials to Overcome Technological Challenges of Microbial Electrolysis Cells
por: Kim, Byeongcheol, et al.
Publicado: (2022)

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
por: Zhao, Liang, et al.
Publicado: (2015)

Overcoming multiple drug resistance mechanisms in medulloblastoma
por: Othman, Ramadhan T, et al.
Publicado: (2014)

Targeted chemotherapy overcomes drug resistance in melanoma
por: Yue, Jingyin, et al.
Publicado: (2020)

Disrupting cellular memory to overcome drug resistance
por: Harmange, Guillaume, et al.
Publicado: (2023)

Retraction: Toxicity evaluation of new engineered nanomaterials in zebrafish
Publicado: (2023)

Retracted: Magnetic Resonance Neuroimaging Contrast Agents of Nanomaterials
por: International, BioMed Research
Publicado: (2023)

Long non-coding RNA HOXA11-AS knockout inhibits proliferation and overcomes drug resistance in ovarian cancer
por: Chen, Yuwei, et al.
Publicado: (2022)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v300cgccrpqvekvj5lk18sfltm